Gilead Sciences ( (GILD) ) has released its Q1 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.
Gilead Sciences, Inc. is a biopharmaceutical company focused on advancing innovative medicines to treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and inflammation, operating in over 35 countries worldwide. In its first quarter of 2025, Gilead Sciences reported stable total revenues of $6.7 billion compared to the previous year, with a notable increase in product sales excluding Veklury by 4% to $6.3 billion. The company highlighted strong performance in its HIV segment, particularly with Biktarvy sales rising by 7% to $3.1 billion, and a significant increase in Descovy sales by 38% to $586 million. Despite a 45% decline in Veklury sales due to reduced COVID-19 hospitalizations, Gilead’s overall financial health showed improvement with a positive net income of $1.3 billion, a turnaround from a loss in the previous year. The company also reported a non-GAAP diluted EPS of $1.81, up from a loss in the same period last year, driven by the absence of prior year charges related to acquisitions. Looking ahead, Gilead remains optimistic about its pipeline, with upcoming regulatory reviews and clinical trials, and maintains its full-year guidance for product sales, excluding Veklury, between $26.8 billion and $27.2 billion.